Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study: BRIGHTEN: double-blind randomized study of ipragliflozin to show its efficacy as monotherapy in T2DM patients
mag(2015)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要